Tofacitinib compared to methotrexate for severe hair loss
Treatments studied
Part of Skin clinical trials.
This study compares two existing medicines — tofacitinib and methotrexate — to see which one is better at treating severe alopecia areata, a condition that causes patchy or total hair loss. If you have severe hair loss, this trial might help you find an effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed by a skin doctor (dermatologist) with severe alopecia areata, which includes total scalp hair loss or total body hair loss.
- You are not currently taking or have not recently taken systemic treatments for hair regrowth, such as oral steroids, immunosuppressants, or JAK inhibitors (like tofacitinib or baricitinib).
- You are not pregnant.
- You have no history or signs of kidney, liver, or lung disease.
- You are able and willing to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a methotrexate lotion or minoxidil lotion is better at regrowing hair in people with patchy hair loss on the scalp. You will use one of the treatments for a period of time, and the doctors will check your progress.
This study compares two medicines, cyclosporine and methotrexate, to see which works better for children with alopecia areata (a condition causing hair loss). It aims to help doctors choose the best treatment for each child.
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study tests a pill called baricitinib (a JAK inhibitor) to see if it can stop rapid hair loss and help hair regrow in people with recent, active alopecia areata. It focuses on those who have been shedding hair for less than three months, so it might stop the process earlier than usual.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.